Bausch Health Cos Cash Flow from Operating Activities 2012-2026 | BHC
Bausch Health Cos cash flow from operating activities from 2012 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
|
Bausch Health Cos Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $1,400 |
| 2024 | $1,597 |
| 2023 | $1,032 |
| 2022 | $-728 |
| 2021 | $1,426 |
| 2020 | $1,111 |
| 2019 | $1,501 |
| 2018 | $1,501 |
| 2017 | $2,290 |
| 2016 | $2,087 |
| 2015 | $2,257 |
| 2014 | $2,312 |
| 2013 | $1,042 |
| 2012 | $657 |
| 2011 | $640 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |